- Home
- LPA vs GOSS Comparison
LPA vs GOSS Comparison
Compare LPA & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPA
- GOSS
- Stock Information
- Founded
- LPA 2013
- GOSS 2015
- Country
- LPA United States
- GOSS United States
- Employees
- LPA N/A
- GOSS N/A
- Industry
- LPA
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- LPA
- GOSS Health Care
- Exchange
- LPA Nasdaq
- GOSS Nasdaq
- Market Cap
- LPA 241.7M
- GOSS 237.9M
- IPO Year
- LPA N/A
- GOSS 2019
- Fundamental
- Price
- LPA $10.02
- GOSS $0.92
- Analyst Decision
- LPA
- GOSS Strong Buy
- Analyst Count
- LPA 0
- GOSS 5
- Target Price
- LPA N/A
- GOSS $9.20
- AVG Volume (30 Days)
- LPA 24.9K
- GOSS 1.0M
- Earning Date
- LPA 02-14-2025
- GOSS 03-04-2025
- Dividend Yield
- LPA N/A
- GOSS N/A
- EPS Growth
- LPA N/A
- GOSS N/A
- EPS
- LPA N/A
- GOSS N/A
- Revenue
- LPA $44,311,428.00
- GOSS $105,322,000.00
- Revenue This Year
- LPA N/A
- GOSS N/A
- Revenue Next Year
- LPA N/A
- GOSS N/A
- P/E Ratio
- LPA N/A
- GOSS N/A
- Revenue Growth
- LPA 22.46
- GOSS N/A
- 52 Week Low
- LPA $6.00
- GOSS $0.50
- 52 Week High
- LPA $525.00
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- LPA N/A
- GOSS 50.80
- Support Level
- LPA N/A
- GOSS $0.83
- Resistance Level
- LPA N/A
- GOSS $1.04
- Average True Range (ATR)
- LPA 0.00
- GOSS 0.10
- MACD
- LPA 0.00
- GOSS -0.01
- Stochastic Oscillator
- LPA 0.00
- GOSS 30.65
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.